Picture of Oncimmune Holdings logo

ONC Oncimmune Holdings News Story

0.000.00%
gb flag iconLast trade - 00:00
HealthcareHighly SpeculativeMicro CapMomentum Trap

RCS - Oncimmune Hldngs PLC - EarlyCDT Lung Partnership Contract Signed

For best results when printing this announcement, please click on link below:
http://pdf.reuters.com/htmlnews/htmlnews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20200521:nRSU5417Na

RNS Number : 5417N  Oncimmune Holdings PLC  21 May 2020

21 May 2020

 

 

Oncimmune Holdings plc

 

("Oncimmune" or the "Company")

 

 EarlyCDT Lung Partnership Contract Signed

 

Oncimmune Holdings plc (AIM: ONC.L), the leading global immunodiagnostics
group, today announces that it has signed a foothill contract to utilise the
Company's EarlyCDT Lung panel to detect incident lung cancer cases in a
screening setting.

 

With one of the world's largest pharmaceutical companies, Oncimmune will
further evaluate EarlyCDT Lung for the detection of lung cancer in at-risk
patients. The initial phase of the collaboration will assess the utility of
Early CDT Lung test at detecting incident lung cancer cases in a screening
setting.

 

We expect this initial phase to be the first step towards a long term
partnership to generate widespread availability of the EarlyCDT Lung test to
improve early detection of lung cancer and facilitate earlier treatment.

 

Adam M Hill, CEO of Oncimmune said: "Over the past two months we have
announced commercial contracts which touch upon the full breadth of
Oncimmune's commercial offering.  Our three year strategy, announced in late
2018, centred on identifying and capitalising upon the wide range of
opportunities presented by Oncimmune's proprietary autoantibody-based
platform. We firmly believe that the momentum we are building validates our
strategy and underpins the commercial potential of our business.

 

We look forward to delivering this work over the coming weeks and announcing
the further development of this partnership."

 

For further information:

 

Oncimmune Holdings plc

Adam Hill, Chief Executive Officer

Matthew Hall, Chief Financial Officer

contact@oncimmune.co.uk (mailto:contact@oncimmune.co.uk)

 

Zeus Capital Limited (Nominated Adviser and Joint Broker)

Andrew Jones, Daniel Harris, Victoria Ayton

+44 (0)20 3829 5000

 

finnCap (Joint Broker)

Geoff Nash, Matthew Radley, Tim Redfern

+44 (0)20 7220 0500

 

Bryan, Garnier & Co Limited (Joint Broker)

Phil Walker, Dominic Wilson

+44 (0)20 7332 2500

 

Media enquiries:

FTI Consulting

Ben Atwell, Michael Trace, Alex Davis

Oncimmune@fticonsulting.com (mailto:Oncimmune@fticonsulting.com)

+44 (0)20 3727 1000

 

 

About Oncimmune

 

Beating cancer, one test at a time

 

The battle against cancer hinges on early detection and then the delivery of
effective treatment. Oncimmune is working to revolutionise both the detection
of cancer and its treatment by harnessing the sophisticated disease detecting
capabilities of the immune system to find cancer in its early stages. Our
range of diagnostic tests assist clinicians to identify the presence of cancer
four years or more before standard clinical diagnosis, whilst our technology
platform and sample biobanks are helping healthcare companies to develop new
cancer treatments.

 

Oncimmune was founded in 2002 and launched its platform technology in 2009,
followed by its first commercial tests, EarlyCDT Lung and EarlyCDT Liver. To
date, over 158,000 tests have been performed for patients worldwide. EarlyCDT
Lung was also used in what is believed to be the largest randomised controlled
trial for the early detection of lung cancer using biomarkers, the successful
National Health Service (NHS) ECLS trial of 12,209 high-risk smokers in
Scotland which demonstrated EarlyCDT Lung reduced the incidence of patients
with late-stage lung cancer or unclassified presentation at diagnosis,
compared to standard clinical practice.

 

Oncimmune, headquartered at its laboratory facility in Nottingham, UK, has a
discovery research centre in Dortmund, Germany and in London, UK and a partner
representative office in Shanghai, China. Oncimmune joined the Alternative
Investment Market (AIM) of the London Stock Exchange in May 2016 under the
ticker ONC.L.

 

What is EarlyCDT Lung?

 

A blood test using a panel of seven immunogenic proteins for the testing of
tumour-related antibodies specific to lung cancer.

 

For more information, visit www.oncimmune.com (http://www.oncimmune.com)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.   END  NRAURONRRUUVUAR

Recent news on Oncimmune Holdings

See all news